<- Go Home

Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Market Cap

EUR 47.4B

Volume

3.1M

Cash and Equivalents

EUR 4.3B

EBITDA

EUR 10.1B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

EUR 27.4B

Profit Margin

60.46%

52 Week High

EUR 53.92

52 Week Low

EUR 24.80

Dividend

0.23%

Price / Book Value

1.60

Price / Earnings

-27.27

Price / Tangible Book Value

-2.40

Enterprise Value

EUR 80.9B

Enterprise Value / EBITDA

7.76

Operating Income

EUR 5.4B

Return on Equity

5.69%

Return on Assets

3.18

Cash and Short Term Investments

EUR 5.1B

Debt

EUR 38.4B

Equity

EUR 29.7B

Revenue

EUR 45.4B

Unlevered FCF

EUR 7.8B

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches